Advanced technology manufacturer Consort Medical has announced a new commercial supply agreement with AstraZeneca for its Bespak proprietary respirator devices.
Bespak
AstraZeneca and Consort Medical announced that they will enter into a multi-year agreement for the scale-up and supply of the Bespak proprietary pressurised metered dose inhaler valves and actuators.
These components will be assembled with AstraZeneca’s Bevespi Aerosphere inhalation aerosol. The device is intended for patients with chronic obstructive pulmonary disease such as chronic bronchitis and/or emphysema. These products will be manufactured in Consort Medical’s Bespak facility in King’s Lynn UK.
Jon Glenn, chief executive officer of Consort Medical, said: “We are delighted to have successfully concluded this agreement with AstraZeneca. This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.”